Overview

Adebrelimab Combined with Apatinib and Gemcitabine and Cisplatin (GP) First-line Treatment for Unresectable Biliary Tract Carcinoma

Status:
RECRUITING

Trial end date:
2027-06-01

Target enrollment:

Participant gender:

Summary

This study is designed to combine anti-angiogenic drugs on the basis of PD-L1+ gemcitabine/cisplatin, hoping to further improve the curative effect of advanced BTC treatment and provide more choices for first-line treatment of BTC in China.

Phase:

PHASE2

Details

Lead Sponsor:

Henan Cancer Hospital

Treatments:

apatinib
Cisplatin
Gemcitabine